logo
logo
AI + EXCLUSIVE DATA

AI tracks executive moves from sources others don't have

Our proprietary AI analyzes exclusive hiring data to find decision-makers actively evaluating solutions like yours.

10-25 executive leads daily • Direct contact info • First 90 days targeting
Start with:
✓Flexible Plans • $39/mo or $29/mo annual
✓AI + proprietary hiring database
✓Executive contact details included
INDUSTRY FIRST

Splice Bio Appoints David Favre, D.V.M., Ph.D., As Chief Development Officer To Accelerate Development of Its Lead Aav Gene Therapy Program

Jun 20, 2023•about 2 years ago

Company

SpliceBio

BarcelonaBiotechnology

Description

SpliceBio, a genetic medicines company exploiting its proprietary Protein Splicing platform to develop next generation gene therapies, is pleased to announce the appointment of David Favre, D.V.M., Ph.D., as Chief Development Officer .

Company Information

Company

SpliceBio

Location

Barcelona, Catalonia, Spain

About

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

Company News

(9 articles)
Wed, 11 Jun 2025 07:00:00 GMT

SpliceBio Nabs $135 Million Series B To Advance Protein Splicing Medicines - BioSpace

Sun, 16 Mar 2025 07:00:00 GMT

SpliceBio Doses First Patient in Trial for Stargardt Gene Therapy SB-007 - CGTLive®

Wed, 11 Jun 2025 07:00:00 GMT

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines - Yahoo Finance

Wed, 11 Jun 2025 07:00:00 GMT

Sanofi-backed SpliceBio secures $135M series B for eye disease gene therapy trials - Fierce Biotech

Wed, 11 Jun 2025 07:00:00 GMT

EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio - Cision News

Wed, 03 Jan 2024 08:00:00 GMT

SpliceBio appoints Aniz Girach as chief medical officer - Ophthalmology Times

Wed, 16 Feb 2022 08:00:00 GMT

Startup Bags €50M Series A to Smash Gene Therapy Vector Limits - Labiotech.eu

Tue, 17 Oct 2023 07:00:00 GMT

SpliceBio sparks up eye disease gene therapy collab with Roche unit - Fierce Biotech

Wed, 16 Feb 2022 08:00:00 GMT

UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapy - Fierce Biotech

FundzWatch™ Score

22
Medium Activity
3 total signals

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months